1. Home
  2. ORMP vs GALT Comparison

ORMP vs GALT Comparison

Compare ORMP & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ORMP
  • GALT
  • Stock Information
  • Founded
  • ORMP 2002
  • GALT 2000
  • Country
  • ORMP United States
  • GALT United States
  • Employees
  • ORMP N/A
  • GALT N/A
  • Industry
  • ORMP Biotechnology: Pharmaceutical Preparations
  • GALT Biotechnology: Pharmaceutical Preparations
  • Sector
  • ORMP Health Care
  • GALT Health Care
  • Exchange
  • ORMP Nasdaq
  • GALT Nasdaq
  • Market Cap
  • ORMP N/A
  • GALT 83.5M
  • IPO Year
  • ORMP N/A
  • GALT N/A
  • Fundamental
  • Price
  • ORMP $2.20
  • GALT $2.18
  • Analyst Decision
  • ORMP Hold
  • GALT Buy
  • Analyst Count
  • ORMP 1
  • GALT 2
  • Target Price
  • ORMP N/A
  • GALT $6.00
  • AVG Volume (30 Days)
  • ORMP 77.2K
  • GALT 1.4M
  • Earning Date
  • ORMP 08-15-2025
  • GALT 08-12-2025
  • Dividend Yield
  • ORMP N/A
  • GALT N/A
  • EPS Growth
  • ORMP N/A
  • GALT N/A
  • EPS
  • ORMP N/A
  • GALT N/A
  • Revenue
  • ORMP $2,000,000.00
  • GALT N/A
  • Revenue This Year
  • ORMP N/A
  • GALT N/A
  • Revenue Next Year
  • ORMP N/A
  • GALT N/A
  • P/E Ratio
  • ORMP N/A
  • GALT N/A
  • Revenue Growth
  • ORMP 196.74
  • GALT N/A
  • 52 Week Low
  • ORMP $1.82
  • GALT $0.73
  • 52 Week High
  • ORMP $3.09
  • GALT $3.90
  • Technical
  • Relative Strength Index (RSI)
  • ORMP 49.72
  • GALT 56.30
  • Support Level
  • ORMP $2.10
  • GALT $2.08
  • Resistance Level
  • ORMP $2.25
  • GALT $2.66
  • Average True Range (ATR)
  • ORMP 0.09
  • GALT 0.53
  • MACD
  • ORMP 0.00
  • GALT -0.02
  • Stochastic Oscillator
  • ORMP 63.16
  • GALT 33.07

About GALT Galectin Therapeutics Inc.

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

Share on Social Networks: